Fuelled by our wider community’s voice of those living with FL, the FLF’s mission is to “cure FL and cure it fast”. This is central to all of our work and all the research we support globally.
In this informative webinar from July 9th 2025, our CMO Dr Mitchell Smith pulls together a stimulating discussion with our expert panellists covering:
Other webinars:
We hold a new webinar usually every other month. To catch up on previous webinars, check out our latest series here where you will find popular topics including “FL treatment options”, “FL and You – Emotional Health and Wellbeing”, and “Understanding FL clinical trials”.
To learn more about our upcoming webinars, including our next one on August 12th 2025, click here, and register your interest today to stay informed about these engaging and informative events.
Watch the full webinar below:
Live feedback from our patient audience:
During the webinar, we asked our live audience “Based on what you learned in this webinar, how would you describe the current outlook for finding a cure for follicular lymphoma?”
Of the 33 respondents, 48% felt that real progress is being made, and we could be looking at a cure in the next 10-15 years. Around 30% felt that a cure could really be found soon – within the next 5 years. The next two biggest challenges were around balancing their emotional health with physical symptoms (16% of responses) and feeling isolated or misunderstood (13% of responses). These themes also came up a lot in the questions that the audience was asking our panel, and so you will hear the speakers talk around these challenges in the full webinar below.
Note: We had some unexpected technical issues towards the end of the webinar. As a result, we plan to follow-up with some additional material to address any missing content and answers to the audience’s questions. More info to come soon!
A heartfelt thank you to those who registered and were also able to attend live, all providing your comments, questions and feedback. Your input is invaluable, and we will continue to address the topics of most importance to you.
[Disclaimer: This webinar is intended for educational and disease awareness purposes only and the information presented and discussed does not constitute medical advice.]
Dr Mitchell Smith – Chief Medical Officer, Follicular Lymphoma Foundation
Dr Mitchell Smith has an extensive educational background, having earned his Medical Degree and PhD from Case Western Reserve University School of Medicine in Cleveland, OH. He has also completed several residencies and fellowships, including a Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Centre in NY. Dr Smith’s career has also spanned many years and institutions, including serving as Director of the Lymphoma Program at Fox Chase Cancer Centre and Director of the Lymphoid Malignancy Program at the Cleveland Clinic. Join him as he shares his expert insights throughout our engaging webinar series.
Prof Jessica Okosun – Scientific Advisor, Follicular Lymphoma Foundation, Professor and Clinician Scientist, Barts Cancer Institute
Prof Okosun is a Consultant Haematologist at St Bartholomew’s Hospital, London UK specialising in lymphomas. Her research interests are focused on understanding how lymphomas initiate, diversify and evolve, particularly follicular lymphoma in a bid to define novel biomarkers and improve treatment. Jessica has been advising the FLF since February 2019.
Paul Christopher Mollitt – Diagnosed 2017
Paul was diagnosed with follicular lymphoma at age 35, after a massage therapist noticed a lump and encouraged him to get it checked. The diagnosis came as a huge shock, but over time, it led to a more intentional approach to life—helping him focus on what matters and live more in the moment. Originally diagnosed in London in 2017, Paul spent seven years on watch and wait, including two years in California, before settling in Spain. In December 2024, following more rapid growth and the discovery of a large abdominal tumour, he began first-line treatment with Bendamustine and Rituximab. He completed treatment in May 2025, achieving a full metabolic response. Paul now hopes for a long remission, giving time for advances in treatment and science—and more time to enjoy life.
Supported by an independent educational grant from AstraZeneca. Sponsorship support from BeOne Medicines USA, Inc. and Novartis, who provided funding. All of the above sponsors have had no influence on, control of, nor input into the development or performance of the webinar series.
